XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.2
License and collaboration agreements - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Jun. 11, 2021
Aug. 31, 2018
Apr. 30, 2017
Sep. 30, 2021
Sep. 30, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]          
License Revenue       $ 104,271,000 $ 104,271,000
Deferred Revenue       520,729,000 520,729,000
Adimab L L C          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Upfront payment received     $ 200,000    
Maximum additional receivable based on achievement of research milestones         14,500,000
Nonrefundable fee to exercise an option   $ 1,000,000.0      
Adimab L L C | License revenue          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
License Revenue         3,400,000
Adimab L L C | Research Collaboration and Option Agreement          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Maximum option fees receivable based on achievement of research milestones per program       400,000 400,000
Adimab L L C | Development Regulatory and Sales Milestone          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Maximum option fees receivable based on achievement of research milestones       45,800,000 45,800,000
GSK          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Upfront payment received $ 625,000,000.0       625,000,000.0
Milestone payments $ 1,450,000        
Eligible royalty payments percentage 20.00%        
Development Milestone         0
GSK Collaboration Agreement          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Deferred Revenue       520,700,000 520,700,000
Costs related to the cost-sharing provisions       1,600,000 1,600,000
Reimbursable by GSK       300,000 300,000
Capitalized contract cost       6,800,000 $ 6,800,000
GSK Collaboration Agreement | License revenue          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
License Revenue       $ 104,300,000